Compare Crispr Therapeutics AG (CRSP) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kraft Heinz Co — how do they compare? Crispr Therapeutics AG trades at $53.3 (market cap $4.88B), while Kraft Heinz Co trades at $22 (market cap $26.66B). The key difference: Kraft Heinz Co is far larger — about 5.5× Crispr Therapeutics AG's market cap, and Kraft Heinz Co pays a 7.12% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Kraft Heinz Co for 129 Days on average.
| CRSP | KHC | |
|---|---|---|
Market Cap | $4.88B | $26.66B |
Volume | 2,861,747 | 31,300,109 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $27.62 |
52-Week Low | $44.34 | $21.21 |
Typical Hold Time | 77 Days | 129 Days |
Enterprise Value | $3.30B | $42.98B |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Kraft Heinz (KHC) trades at $21.98, down 0.23% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though it has beaten EPS estimates for three consecutive quarters. Positive operating cash flow of $4.46 billion and a dividend yield near 7.3% provide some support, but high debt and declining revenue pose challenges.
The outlook remains cautious with a consensus price target of $23.78 suggesting modest upside. Risks include persistent volume declines, high leverage, and competitive pressures. The stock's deep value metrics (P/E of 13.04, P/B of 0.74) may attract contrarian investors, but sustained profitability improvement is needed for a durable rebound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
